Floatz logo

Rimegepant

Photosensitivity Disease

PfizerSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Photosensitivity Disease cohort.

Asset / SponsorPhaseRating
Pro-513
ProEthic Pharmaceuticals
Phase 3BB

Same molecule, other indications

Rimegepant is also rated in:

migraine disorderActive
BBB
Indicative · Phase 4
75 / 100
View asset →
migraine without auraActive
BB
Indicative · Phase 4
69 / 100
View asset →
migraine with auraActive
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →